STOCK TITAN

Lam Research officer sells 59,750 shares at $291

Lam Research’s senior vice president exercised options and sold 59,750 shares under a pre-arranged Rule 10b5-1 trading plan.

(Very High)
(Very Negative)
Form Type
4

Rhea-AI Filing Summary

LAM RESEARCH CORP (LRCX) senior vice president Varadarajan Seshasayee reported option exercises and related stock sales on September 2, 2026. He exercised employee stock options for 39,750 shares of common stock at exercise prices of $59.881 and $30.033 per share, and sold a total of 59,750 shares of common stock at $291.32 per share pursuant to a Rule 10b5-1 trading plan adopted on May 4, 2026. He also reports indirect ownership of 2,366.911 shares of common stock through a 401(k) plan, and a footnote states that his reported holdings include shares underlying unvested restricted stock units.

Positive

  • None.

Negative

  • None.

Insights

Analyzing...

Insider Varadarajan Seshasayee
Role Senior Vice President
Sold 59,750 shs ($17.41M)
Approx. gross sale proceeds $17.41M
Approx. exercise cost $1.56M
Type Security Shares Price Value
Exercise Employee Stock Option (Right to Buy) F3 12,270 $0.00 $0.00
Exercise Employee Stock Option (Right to Buy) F4 27,480 $0.00 $0.00
Sale Common Stock F1, F2 20,000 $291.32 $5.83M
Exercise Common Stock F1, F2 12,270 $59.881 $735K
Sale Common Stock F1, F2 12,270 $291.32 $3.57M
Exercise Common Stock F1, F2 27,480 $30.033 $825K
Sale Common Stock F1, F2 27,480 $291.32 $8.01M
holding Common Stock -- -- --
Holdings After Transaction: Employee Stock Option (Right to Buy) — 0 contracts (Direct); Common Stock — 205,546 shares (Direct); Common Stock — 2,366.911 shares (Indirect, By 401(k))
Footnotes (4)
  1. F1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 4, 2026.
  2. F2. The amount reported includes shares subject to unvested restricted stock units.
  3. F3. The stock options will become exercisable in three equal installments on 03/01/2022, 03/01/2023, and 03/01/2024.
  4. F4. The stock options will become exercisable in three equal installments on 03/02/2021, 03/02/2022, and 03/02/2023.
Shares sold 59,750 shares Total Lam Research common shares sold on September 2, 2026
Sale price per share $291.32 per share Price for Lam Research common stock sales on September 2, 2026
Options exercised (shares) 39,750 shares Common shares received from option exercises on September 2, 2026
Option exercise price $59.881 per share Exercise price for 12,270 options expiring March 1, 2028
Option exercise price $30.033 per share Exercise price for 27,480 options expiring March 2, 2027
Indirect 401(k) holdings 2,366.911 shares Lam Research common stock held indirectly through a 401(k) plan
Net sell shares 59,750 shares Net shares sold in buy/sell summary for this Form 4
Rule 10b5-1 trading plan regulatory
"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
restricted stock units financial
"The amount reported includes shares subject to unvested restricted stock units"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Employee Stock Option (Right to Buy) financial
"Employee Stock Option (Right to Buy) reported as a derivative security"
indirect ownership financial
"Common stock held indirectly by 401(k) is reported as indirect ownership"

FAQ

What did LRCX executive Varadarajan Seshasayee report in this Form 4?

Varadarajan Seshasayee reported exercising 39,750 options for Lam Research common stock and selling 59,750 shares of common stock on September 2, 2026, with transactions carried out under a Rule 10b5-1 trading plan.

How many Lam Research (LRCX) shares did the insider sell and at what price?

He sold a total of 59,750 shares of Lam Research common stock at a reported price of $291.32 per share on September 2, 2026, in a series of sale transactions linked to his option exercises.

What options did the LRCX insider exercise in this filing?

He exercised 12,270 options with an exercise price of $59.881 per share, expiring March 1, 2028, and 27,480 options with an exercise price of $30.033 per share, expiring March 2, 2027, receiving the same number of Lam Research common shares.

Were the LRCX insider trades made under a Rule 10b5-1 plan?

Yes. A footnote states the transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 4, 2026, and the Form 4 indicates affirmation of trades under such a plan.

What Lam Research (LRCX) shares does the insider still hold indirectly?

The Form 4 reports 2,366.911 shares of Lam Research common stock held indirectly through a 401(k) plan. Another footnote notes that the total reported holdings include shares subject to unvested restricted stock units.

What is the net share effect of the Form 4 transactions for LRCX?

Across all reported trades, there were 59,750 shares sold of Lam Research common stock and 39,750 shares acquired through option exercises, resulting in a net disposition of 59,750 shares in the buy/sell summary.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Varadarajan Seshasayee

(Last)(First)(Middle)
C/O LAM RESEARCH CORPORATION
4650 CUSHING PARKWAY

(Street)
FREMONT CALIFORNIA 94538

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
LAM RESEARCH CORP [ LRCX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Senior Vice President
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
09/02/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock09/02/2026S20,000D$291.32(1)205,546(2)D
Common Stock09/02/2026M12,270A$59.881(1)217,816(2)D
Common Stock09/02/2026S12,270D$291.32(1)205,546(2)D
Common Stock09/02/2026M27,480A$30.033(1)233,026(2)D
Common Stock09/02/2026S27,480D$291.32(1)205,546(2)D
Common Stock2,366.911IBy 401(k)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Employee Stock Option (Right to Buy)$59.88109/02/2026M12,270 (3)03/01/2028Common Stock12,270$00D
Employee Stock Option (Right to Buy)$30.03309/02/2026M27,480 (4)03/02/2027Common Stock27,480$00D
Explanation of Responses:
1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 4, 2026.
2. The amount reported includes shares subject to unvested restricted stock units.
3. The stock options will become exercisable in three equal installments on 03/01/2022, 03/01/2023, and 03/01/2024.
4. The stock options will become exercisable in three equal installments on 03/02/2021, 03/02/2022, and 03/02/2023.
Remarks:
Marta Woods by Power of Attorney09/03/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)